Capital Increase in Genmab as a Result of Employee Warrant Exercise
April 03, 2018 12:28 ET
|
Genmab A/S
Company Announcement Copenhagen, Denmark; April 3, 2018 – Genmab A/S (Nasdaq Copenhagen: GEN) will increase its share capital by 30,149 shares as a consequence of the exercise of...
Genmab A/S Summons Annual General Meeting
March 08, 2018 02:26 ET
|
Genmab A/S
Company Announcement
Genmab A/S to hold Annual General Meeting on April 10, 2018
Copenhagen, Denmark; March 8, 2018 – Genmab A/S (Nasdaq Copenhagen: GEN) summons the Annual...
Selskabsvedtægter for Genmab A/S
March 01, 2018 09:46 ET
|
Genmab A/S
Selskabsvedtægter for Genmab A/S dateret den 28. februar 2018 er blevet offentliggjort. Selskabsvedtægterne er tilgængelige på Genmabs hjemmeside:...
Articles of Association for Genmab A/S
March 01, 2018 09:46 ET
|
Genmab A/S
Genmab A/S has published its Articles of Association dated February 28, 2018. The Articles of Association can be found on Genmab’s website: http://ir.genmab.com/releases.cfm
Contact:
Rachel...
Capital Increase in Genmab as a Result of Employee Warrant Exercise
February 28, 2018 12:31 ET
|
Genmab A/S
Company Announcement
Copenhagen, Denmark; February 28, 2018 – Genmab A/S (Nasdaq Copenhagen: GEN) will increase its share capital by 65,419 shares as a consequence of the exercise of employee...
Genmab 2017 Annual Report
February 21, 2018 11:02 ET
|
Genmab A/S
Company Announcement
Copenhagen, Denmark; February 21, 2018 – Genmab A/S (Nasdaq Copenhagen: GEN) announced today its Annual Report for 2017. Below is a summary of business progress...
Genmab Announces 2017 Net Sales Figures for DARZALEX® (Daratumumab)
January 23, 2018 06:50 ET
|
Genmab A/S
Company Announcement
Net sales of DARZALEX in 2017 totaled USD 1,242 million
Genmab receives royalties on worldwide sales from Janssen Biotech, Inc.
Copenhagen,...
Genmab Announces Novartis’ Intention to Transition Arzerra® (ofatumumab) from Commercial Availability to Limited Availability via Compassionate Use Programs for the Treatment of CLL in Non-US Markets
January 22, 2018 02:06 ET
|
Genmab A/S
Company Announcement
Novartis intends to transition the commercial availability of Arzerra to limited availability via compassionate use programs for treatment of CLL in non-US markets....
U.S. FDA Grants Priority Review for Daratumumab in Front Line Multiple Myeloma
January 19, 2018 17:27 ET
|
Genmab A/S
Company Announcement
U.S. FDA grants Priority Review to daratumumab in combination with bortezomib, melphalan and prednisone for the treatment of patients with newly diagnosed multiple myeloma...
Major Shareholder Announcement
January 09, 2018 14:58 ET
|
Genmab A/S
Company Announcement
Major shareholder announcement for Genmab A/S
Copenhagen, Denmark; January 9, 2018 – Genmab A/S (Nasdaq Copenhagen: GEN) announces under reference to Section 29 of the...